Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 14/20 | 0.45 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.38 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5134636 | 0.95 | AGTR1 (0.46) | AGTR1AGTR2KDM4EALDH1A1MAPT | |
| SCHEMBL5135023 | 0.92 | AGTR1 (0.45) | AGTR1AGTR2MAPTSMN1; SMN2LPAR1 | |
| SCHEMBL5135175 | 0.92 | AGTR1 (0.43) | AGTR1AGTR2KDM4EALDH1A1MAPT | |
| SCHEMBL5136167 | 0.90 | AGTR1 (0.43) | AGTR1AGTR2 | |
| SCHEMBL5072498 | 0.88 | TSHR (0.45) | KDM4EALDH1A1 | |
| SCHEMBL1913103 | 0.86 | C5AR1 (0.46) | AGTR1ALDH1A1MAPT | |
| SCHEMBL5138002 | 0.86 | C5AR1 (0.51) | AGTR1KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5136832 | 0.86 | TSHR (0.42) | AGTR1KDM4EALDH1A1 | |
| SCHEMBL5212722 | 0.86 | AGTR1 (0.43) | AGTR1AGTR2KDM4EALDH1A1MAPT | |
| SCHEMBL5135282 | 0.85 | ALDH1A1 (0.37) | AGTR1KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |